This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
Protocol Amendment History
37 amendments
This ClinicalTrials.gov record has been amended 37 times since 2022-06-06; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting2022-07-13